Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

While this adds competition to a market currently controlled by Eli Lilly LLY 0.13%increase; green up pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...